Jun Takeuchi
Sapporo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Clinical efficacy of switching to tirzepatide in patients with type 2 diabetes and a high risk of metabolic dysfunction-associated steatotic liver disease undergoing GLP-1 receptor agonist therapy: Insights from the Hokkaido-TZP study.
Journal: Journal of diabetes and its complications
Published: May 28, 2026
Real-World Clinical Evidence of Tirzepatide for Metabolic Abnormalities in Subjects With Type 2 Diabetes: The Multicenter Retrospective Observational Hokkaido-TZP Study.
Journal: Diabetes, obesity & metabolism
Published: February 05, 2026
The Effects of Oral Semaglutide on Hepatic Fibrosis in Subjects with Type 2 Diabetes in Real-World Clinical Practice: A Post Hoc Analysis of the Sapporo-Oral SEMA Study.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: December 20, 2024
Real-world clinical evidence of oral semaglutide on metabolic abnormalities in subjects with type 2 diabetes: a multicenter retrospective observational study (the Sapporo-Oral SEMA study).
Journal: Endocrine journal
Published: April 24, 2024
Improvement of β-Cell Function After Switching From DPP-4 Inhibitors to Oral Semaglutide: SWITCH-SEMA2 Post Hoc Analysis.
Journal: The Journal of clinical endocrinology and metabolism
Published: January 04, 2024
Glycaemic control efficacy of switching from dipeptidyl peptidase-4 inhibitors to oral semaglutide in subjects with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 2 study).
Journal: Diabetes, obesity & metabolism
Published: October 13, 2023
Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damage.
Journal: Diabetology & metabolic syndrome
Published: July 23, 2023
Hand function and quality of life in patients with diabetes mellitus before and during the COVID-19 pandemic.
Journal: Nagoya journal of medical science
Published: June 01, 2023
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Journal: Diabetes, obesity & metabolism
Published: November 25, 2022
Effects of pemafibrate on lipid metabolism in patients with type 2 diabetes and hypertriglyceridemia: A multi-center prospective observational study, the PARM-T2D study.
Journal: Diabetes research and clinical practice
Published: July 29, 2022
Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, parallel-group comparison study (MEGMI study).
Journal: BMJ open diabetes research & care
Published: June 13, 2022
Last Updated: 09/26/2026